The association between type 2 diabetes mellitus and women cancer: The epidemiological evidences and putative mechanisms

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Joung, Kyong Hye ^a   Jeong, Jae Wook ^a,b   Ku, Bon Jeong ^a  

^a Chungnam National University   (South Korea)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN DERIVATIVE; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 1; INTERLEUKIN 6; METALLOPROTEINASE; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROGESTERONE; RAS PROTEIN; ROSIGLITAZONE; SEX HORMONE BINDING PROTEIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CHRONIC INFLAMMATION; COMORBIDITY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ENVIRONMENTAL EXPOSURE; ETHNICITY; GENE MUTATION; GLYCEMIC CONTROL; GYNECOLOGIC CANCER; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARIAN CANCER CELL LINE; OVARY CANCER; PHYSICAL ACTIVITY; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; METABOLISM; NEOPLASMS; PATHOLOGY;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; NEOPLASMS;

EID: 84926442269     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/920618     Document Type: Review

References (207)

1. W. Rathmann, G. Giani, S. H. Wild et al., "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030," Diabetes Care, Vol. 27, no. 10, pp. 2568-2569, 2004.
2. P. Zhang, X. Zhang, J. Brown et al., "Global healthcare expenditure on diabetes for 2010 and 2030," Diabetes Research and Clinical Practice, Vol. 87, no. 3, pp. 293-301, 2030.
3. P. T. Campbell, E. J. Jacobs, C. C. Newton, S. M. Gapstur, and A. V. Patel, "Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults," Diabetes Care, Vol. 35, no. 9, pp. 1835-1844, 2012.
4. S. R. Seshasai, S. Kaptoge, A. Thompson et al., "Diabetes mellitus, fasting glucose, and risk of cause-specific death," The New England Journal of Medicine, Vol. 364, no. 9, pp. 829-841, 2011.
5. S. S. Coughlin, E. E. Calle, L. R. Teras, J. Petrelli, and M. J. Thun, "Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults," American Journal of Epidemiology, Vol. 159, no. 12, pp. 1160-1167, 2004.
6. S. D. Nath, S. L. Habib, H. E. Abboud et al., "Fasting serum glucose level and cancer risk in Korean men and women," Journal of the American Medical Association, Vol. 293, no. 18, pp. 2210-2211, 2005.
7. G. Chodick, A. D. Heymann, L. Rosenmann et al., "Diabetes and risk of incident cancer: a large population-based cohort study in Israel," Cancer Causes and Control, Vol. 21, no. 6, pp. 879-887, 2010.
8. E. K. K. Lam, G. D. Batty, R. R. Huxley et al., "Associations of diabetes mellitus with site-specific cancer mortality in the Asia-Pacific region," Annals of Oncology, Vol. 22, no. 3, pp. 730-738, 2011.
9. Y. Handelsman, D. Leroith, Z. T. Bloomgarden et al., "Diabetes and cancer - an AACE/ACE consensus statement," Endocrine Practice, Vol. 19, no. 4, pp. 675-693, 2013.
10. A. Czyzyk and Z. Szczepanik, "Diabetes mellitus and cancer," European Journal of Internal Medicine, Vol. 11, no. 5, pp. 245-252, 2000.
11. S. C. Larsson, C. S. Mantzoros, and A. Wolk, "Diabetes mellitus and risk of breast cancer: a meta-analysis," International Journal of Cancer, Vol. 121, no. 4, pp. 856-862, 2007.
12. S. C. Larsson, N. Orsini, and A. Wolk, "Diabetes mellitus and risk of colorectal cancer: a meta-analysis," Journal of the National Cancer Institute, Vol. 97, no. 22, pp. 1679-1687, 2005.
13. E. Friberg, N. Orsini, C. S. Mantzoros, and A. Wolk, "Diabetes mellitus and risk of endometrial cancer: a meta-analysis," Diabetologia, Vol. 50, no. 7, pp. 1365-1374, 2007.
14. E. M. Ko, P. Walter, L. Clark et al., "The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance," Gynecologic Oncology, Vol. 133, no. 1, pp. 28-32, 2014.
15. H.-F. Chen, M.-D. Liu, P. Chen et al., "Risks of breast and endometrial cancer in women with diabetes: a population-based cohort study," PLoS ONE, Vol. 8, no. 6, Article ID e67420, 2013.
16. R. Huxley, A. Ansary-Moghaddam, A. Berrington de González, F. Barzi, and M. Woodward, "Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies," British Journal of Cancer, Vol. 92, no. 11, pp. 2076-2083, 2005.
17. H. B. El-Serag, H. Hampel, and F. Javadi, "The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence," Clinical Gastroenterology and Hepatology, Vol. 4, no. 3, pp. 369-380, 2006.
18. H. Fang, B. Yao, Y. Yan et al., "Diabetes mellitus increases the risk of bladder cancer: an updated meta-analysis of observational studies," Diabetes Technology and Therapeutics, Vol. 15, no. 11, pp. 914-922, 2013.
19. B. B. Barone, H.-C. Yeh, C. F. Snyder et al., "Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis," The Journal of the American Medical Association, Vol. 300, no. 23, pp. 2754-2764, 2008.
20. R. Clarke, M. Shipley, S. Lewington et al., "Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies," The American Journal of Epidemiology, Vol. 150, no. 4, pp. 341-353, 1999.
21. S. L. Habib and M. Rojna, "Diabetes and risk of cancer," ISRN Oncology, Vol. 2013, Article ID 583786, 16 pages, 2013.
22. F. Ikeda, Y. Doi, K. Yonemoto et al., "Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection: a population-based cohort study," Gastroenterology, Vol. 136, no. 4, pp. 1234-1241, 2009.
23. T. N. Le, J. E. Nestler, J. F. Strauss, and E. P. Wickham, "Sex hormone-binding globulin and type 2 diabetes mellitus," Trends in Endocrinology & Metabolism, Vol. 23, no. 1, pp. 32-40, 2012.
24. S. K. Pal and A. Hurria, "Impact of age, sex, and comorbidity on cancer therapy and disease progression," Journal of Clinical Oncology, Vol. 28, no. 26, pp. 4086-4093, 2010.
25. J. H. Koo and R. W. L. Leong, "Sex differences in epidemiological, clinical and pathological characteristics of colorectal cancer," Journal of Gastroenterology and Hepatology, Vol. 25, no. 1, pp. 33-42, 2010.
26. M. Pollak, "Insulin and insulin-like growth factor signalling in neoplasia," Nature Reviews Cancer, Vol. 8, no. 12, pp. 915-928, 2008.
27. J. A. Cooper, D. F. Bowen-Pope, E. Raines, R. Ross, and T. Hunter, "Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins," Cell, Vol. 31, no. 1, pp. 263-273, 1982.
28. N. Chegini, M. J. Rossi, and B. J. Masterson, "Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and EGF and PDGF β-receptors in human endometrial tissue: localization and in vitro action," Endocrinology, Vol. 130, no. 4, pp. 2373-2385, 1992.
29. Z. Laron, "IGF-1 and insulin as growth hormones," Novartis Foundation Symposium, Vol. 262, pp. 56-83, 265-268, 2004.
30. V. Pezzino, A. Costantino, P. Russo, D. Gullo, and V. Papa, "Insulin receptor content in tissues of normal and diabetic rats measured by radioimunoassay," Journal of Endocrinological Investigation, Vol. 19, no. 9, pp. 593-597, 1996.
31. C. Hernández-Sánchez, A. Mansilla, F. De Pablo, and R. Zardoya, "Evolution of the insulin receptor family and receptor isoform expression in vertebrates," Molecular Biology and Evolution, Vol. 25, no. 6, pp. 1043-1053, 2008.
32. P. de Meyts, "Insulin and its receptor: structure, function and evolution," BioEssays, Vol. 26, no. 12, pp. 1351-1362, 2004.
33. E. S. Schernhammer, J. M. Holly, D. J. Hunter, M. N. Pollak, and S. E. Hankinson, "Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II," Endocrine-Related Cancer, Vol. 13, no. 2, pp. 583-592, 2006.
34. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri, "Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease," Endocrine Reviews, Vol. 30, no. 6, pp. 586-623, 2009.
35. S. Benyoucef, K. H. Surinya, D. Hadaschik, and K. Siddle, "Characterization of insulin/IGF hybrid receptors: contributions of the insulin receptor L2 and Fn1 domains and the alternatively spliced exon 11 sequence to ligand binding and receptor activation," Biochemical Journal, Vol. 403, no. 3, pp. 603-613, 2007.
36. D. LeRoith, "Insulin-like growth factor I receptor signaling - overlapping or redundant pathways?" Endocrinology, Vol. 141, no. 4, pp. 1287-1288, 2000.
37. P. J. Jenkins, "Cancers associated with acromegaly," Neuroen-docrinology, Vol. 83, no. 3-4, pp. 218-223, 2006.
38. E. E. Calle, C. Rodriguez, K. Walker-Thurmond, and M. J. Thun, "Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults," The New England Journal of Medicine, Vol. 348, no. 17, pp. 1625-1638, 2003.
39. D. L. Roberts, C. Dive, and A. G. Renehan, "Biological mechanisms linking obesity and cancer risk: new perspectives," Annual Review of Medicine, Vol. 61, pp. 301-316, 2010.
40. D. H. Cohen and D. LeRoith, "Obesity, type 2 diabetes, and cancer: the insulin and IGF connection," Endocrine-Related Cancer, Vol. 19, no. 5, pp. F27-F45, 2012.
41. Y. Gu, C. Wang, Y. Zheng et al., "Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: a cohort study in Shanghai," PLoS ONE, Vol. 8, no. 1, Article ID e53411, 2013.
42. J. Ma, H. Li, E. Giovannucci et al., "Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis," The Lancet Oncology, Vol. 9, no. 11, pp. 1039-1047, 2008.
43. J. Ma, E. Giovannucci, M. Pollak et al., "A prospective study of plasma C-peptide and colorectal cancer risk in men," Journal of the National Cancer Institute, Vol. 96, no. 7, pp. 546-553, 2004.
44. R. Dankner, M. H. Shanik, L. Keinan-Boker, C. Cohen, and A. Chetrit, "Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study," Diabetes Care, Vol. 35, no. 7, pp. 1538-1543, 2012.
45. M. Lippman, G. Bolan, and K. Huff, "The effects of estrogens and antiestrogens on hormone responsive human breast cancer in long term tissue culture," Cancer Research, Vol. 36, no. 12, pp. 4595-4601, 1976.
46. C. K. Osborne, G. Bolan, M. E. Monaco, and M. E. Lippman, "Hormone responsive human breast cancer in long term tissue culture: effect of insulin," Proceedings of the National Academy of Sciences of the United States of America, Vol. 73, no. 12, pp. 4536-4540, 1976.
47. H. Zhang, D. H. Fagan, X. Zeng, K. T. Freeman, D. Sachdev, and D. Yee, "Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation," Oncogene, Vol. 29, no. 17, pp. 2517-2527, 2010.
48. J.C. Heuson and N. Legros, "Influence ofinsulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction.," Cancer Research, Vol. 32, no. 2, pp. 226-232, 1972.
49. S. M. Firth and R. C. Baxter, "Cellular actions of the insulin-like growth factor binding proteins," Endocrine Reviews, Vol. 23, no. 6, pp. 824-854, 2002.
50. V. A. Ezzat, E. R. Duncan, S. B. Wheatcroft, and M. T. Kearney, "The role of IGF-I and its binding proteins in the development of type 2 diabetes and cardiovascular disease," Diabetes, Obesity and Metabolism, Vol. 10, no. 3, pp. 198-211, 2008.
51. S. Söderberg, B. Ahrén, M. Eliasson, B. Dinesen, K. Brismar, and T. Olsson, "Circulating IGF binding protein-1 is inversely associated with leptin innon-obese men and obese postmenopausal women," European Journal of Endocrinology, Vol. 144, no. 3, pp. 283-290, 2001.
52. A. López-Bermejo, J. Khosravi, J. M. Fernández-Real et al., "Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25)," Diabetes, Vol. 55, no. 8, pp. 2333-2339, 2006.
53. D. P. Rose and L. Vona-Davis, "The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression," Endocrine-Related Cancer, Vol. 19, no. 6, pp. R225-R241, 2012.
54. N. Mu, Y. Zhu, Y. Wang, H. Zhang, and F. Xue, "Insulin resistance: a significant risk factor of endometrial cancer," Gynecologic Oncology, Vol. 125, no. 3, pp. 751-757, 2012.
55. M. C. Beauchamp, A. Yasmeen, A. Knafo, and W. H. Gotlieb, "Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer," Journal of Oncology, Vol. 2010, Article ID 257058, 11 pages, 2010.
56. M. Pollak, "The insulin and insulin-like growth factor receptor family in neoplasia: an update," Nature Reviews Cancer, Vol. 12, no. 3, pp. 159-169, 2012.
57. P. K. Siiteri, "Steroid hormones and endometrial cancer," Cancer Research, Vol. 38, no. 11, part 2, pp. 4360-4366, 1978.
58. T. J. A. Key and M. C. Pike, "The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk," British Journal of Cancer, Vol. 57, no. 2, pp. 205-212, 1988.
59. A. Lukanovaand R. Kaaks, "Endogenous hormones andovarian cancer: epidemiology and current hypotheses," Cancer Epidemiology Biomarkers and Prevention, Vol. 14, no. 1, pp. 98-107, 2005.
60. A. Ferenczy, G. Bertrand, and M. M. Gelfand, "Proliferation kinetics of human endometrium during the normal menstrual cycle," American Journal of Obstetrics & Gynecology, Vol. 133, no. 8, pp. 859-867, 1979.
61. C. L. Wilson, A. H. Sims, A. Howell, C. J. Miller, and R. B. Clarke, "Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue," Endocrine-Related Cancer, Vol. 13, no. 2, pp. 617-628, 2006.
62. J. Stingl, "Estrogen and progesterone in normal mammary gland development and in cancer," Hormones and Cancer, Vol. 2, no. 2, pp. 85-90, 2011.
63. R. F. Spengler, E. A. Clarke, C. A. Woolever, A. M. Newman, and R. W. Osborn, "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases," American Journal of Epidemiology, Vol. 114, no. 4, pp. 497-506, 1981.
64. E. J. Crosbie, M. Zwahlen, H. C. Kitchener, M. Egger, and A. G. Renehan, "Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis," Cancer Epidemiology Biomarkers and Prevention, Vol. 19, no. 12, pp. 3119-3130, 2010.
65. K. K. Steinberg, S. B. Thacker, S. J. Smith et al., "A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer," The Journal of the American Medical Association, Vol. 265, no. 15, pp. 1985-1990, 1991.
66. C. Magnusson, I. Persson, and H.-O. Adami, "More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin," Journal of the National Cancer Institute, Vol. 92, no. 14, pp. 1183-1184, 2000.
67. P. G. Toniolo, M. Levitz, A. Zeleniuch-Jacquotte et al., "A prospective study of endogenous estrogens and breast cancer in postmenopausal women," Journal of the National Cancer Institute, Vol. 87, no. 3, pp. 190-197, 1995.
68. A. Akhmedkhanov, A. Zeleniuch-Jacquotte, and P. Toniolo, "Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives," Annals of the New York Academy of Sciences, Vol. 943, pp. 296-315, 2001.
69. C. M. Friedenreich, "Review of anthropometric factors and breast cancer risk," European Journal of Cancer Prevention, Vol. 10, no. 1, pp. 15-32, 2001.
70. S. C. Sommers, A. T. Hertig, and H. Bengloff, "Genesis of endometrial carcinoma; cases 19 to 35 years old," Cancer, Vol. 2, no. 6, pp. 957-963, 1949.
71. E. Ron, B. Lunenfeld, J. Menczer et al., "Cancer incidence in a cohort of infertile women," American Journal of Epidemiology, Vol. 125, no. 5, pp. 780-790, 1987.
72. S. Wild, T. Pierpoint, H. Jacobs, and P. McKeigue, "Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study," Human Fertility, Vol. 3, no. 2, pp. 101-105, 2000.
73. C. B. Coulam, J. F. Annegers, and J. S. Kranz, "Chronic anovulation syndrome and associated neoplasia," Obstetrics and Gynecology, Vol. 61, no. 4, pp. 403-407, 1983.
74. A. Daniilidis and K. Dinas, "Long term health consequences of polycystic ovarian syndrome: a review analysis," Hippokratia, Vol. 13, no. 2, pp. 90-92, 2009.
75. N. Potischman, R. N. Hoover, L. A. Brinton et al., "Case-control study of endogenous steroid hormones and endometrial cancer," Journal of the National Cancer Institute, Vol. 88, no. 16, pp. 1127-1135, 1996.
76. B. Pettersson, R. Bergstrom, and E. D. B. Johansson, "Serum estrogens and androgens in women with endometrial carcinoma," Gynecologic Oncology, Vol. 25, no. 2, pp. 223-233, 1986.
77. H. C. J. Nyholm, A. L. Nielsen, J. Lyndrup, A. Dreisler, C. Hagen, and E. Haug, "Plasma oestrogens in postmenopausal women with endometrial cancer," British Journal of Obstetrics and Gynaecology, Vol. 100, no. 12, pp. 1115-1119, 1993.
78. J. A. Nisker, G. L. Hammond, B. J. Davidson et al., "Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma," American Journal of Obstetrics and Gynecology, Vol. 138, no. 6, pp. 637-642, 1980.
79. J. M. Schildkraut, P. J. Schwingl, E. Bastos, A. Evanoff, C. Hughes, and J. P. Curtin, "Epithelial ovarian cancer risk among women with polycystic ovary syndrome," Obstetrics & Gynecology, Vol. 88, no. 4, part 1, pp. 554-559, 1996.
80. E. G. Silva, C. Tornos, H. A. Fritsche Jr. et al., "The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model," Modern Pathology, Vol. 10, no. 9, pp. 879-883, 1997.
81. I. Wiegratz, C. Jung-Hoffmann, and H. Kuhl, "Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins," Contraception, Vol. 51, no. 6, pp. 341-346, 1995.
82. N. Fortunati, M. G. Catalano, G. Boccuzzi, and R. Frairia, "Sex Hormone-Binding Globulin (SHBG), estradiol and breast cancer," Molecular and Cellular Endocrinology, Vol. 316, no. 1, pp. 86-92, 2010.
83. G. N. Armaiz-Pena, L. S. Mangala, W. A. Spannuth et al., "Estrous cycle modulates ovarian carcinoma growth," Clinical Cancer Research, Vol. 15, no. 9, pp. 2971-2978, 2009.
84. C.-H. Chien, F.-F. Wang, and T. C. Hamilton, "Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells," Molecular and Cellular Endocrinology, Vol. 99, no. 1, pp. 11-19, 1994.
85. A. V. Lee, J. G. Jackson, J. L. Gooch et al., "Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo," Molecular Endocrinology, Vol. 13, no. 5, pp. 787-796, 1999.
86. L. C. Giudice, G. Lamson, R. G. Rosenfeld, and J. C. Irwin, "Insulin-like growth factor-II (IGF-II) and IGF binding proteins in human endometrium," Annals of the New York Academy of Sciences, Vol. 626, pp. 295-307, 1991.
87. L. J. Murphy and A. Ghahary, "Uterine insulin-like growth factor-1: regulation of expression and its role in estrogeninduced uterine proliferation," Endocrine Reviews, Vol. 11, no. 3, pp. 443-453, 1990.
88. V. Bartella, P. de Marco, R. Malaguarnera, A. Belfiore, and M. Maggiolini, "New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer," Cellular Signalling, Vol. 24, no. 8, pp. 1515-1521, 2012.
89. D. H. Fagan, R. R. Uselman, D. Sachdev, and D. Yee, "Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment," Cancer Research, Vol. 72, no. 13, pp. 3372-3380, 2012.
90. T. Winder, G. Giamas, P. M. Wilson et al., "Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen," Pharmacogenomics Journal, Vol. 14, no. 1, pp. 28-34, 2014.
91. + breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim," Breast Cancer Research, Vol. 14, no. 2, p. R52, 2012.
92. V. Syed, G. Ulinski, S. C. Mok, and S.-M. Ho, "Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells," Journal of the National Cancer Institute, Vol. 94, no. 8, pp. 617-629, 2002.
93. M. Qiu, W. Bao, J. Wang et al., "FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer," BMC Cancer, Vol. 14, no. 1, article 78, 2014.
94. L. E. Underwood, J.-P. Thissen, S. Lemozy, J.-M. Ketelslegers, and D. R. Clemmons, "Hormonal and nutritional regulation of IGF-I and its binding proteins," Hormone Research, Vol. 42, no. 4-5, pp. 145-151, 1994.
95. J.-P. Thissen, J.-M. Ketelslegers, and L. E. Underwood, "Nutritional regulation of the insulin-like growth factors," Endocrine Reviews, Vol. 15, no. 1, pp. 80-101, 1994.
96. R. Pasquali, V. Vicennati, D. Bertazzo et al., "Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status," Metabolism: Clinical and Experimental, Vol. 46, no. 1, pp. 5-9, 1997.
97. D. P. Rose, D. Komninou, and G. D. Stephenson, "Obesity, adipocytokines, and insulin resistance in breast cancer," Obesity Reviews, Vol. 5, no. 3, pp. 153-165, 2004.
98. D. Pardoll, "Does the immune system see tumors as foreign or self?" Annual Review of Immunology, Vol. 21, pp. 807-839, 2003.
99. M. Philip, D. A. Rowley, and H. Schreiber, "Inflammation as a tumor promoter in cancer induction," Seminars in Cancer Biology, Vol. 14, no. 6, pp. 433-439, 2004.
100. J.-L. Luo, S. Maeda, L.-C. Hsu, H. Yagita, and M. Karin, "Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression," Cancer Cell, Vol. 6, no. 3, pp. 297-305, 2004.
101. M. Karin and F. R. Greten, "NF-κB: linking inflammation and immunity to cancer development and progression," Nature Reviews Immunology, Vol. 5, no. 10, pp. 749-759, 2005.
102. K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, "Metabolic syndrome and risk of cancer: a systematic review and meta-analysis," Diabetes Care, Vol. 35, no. 11, pp. 2402-2411, 2012.
103. P. Pothiwala, S. K. Jain, and S. Yaturu, "Metabolic syndrome and cancer," Metabolic Syndrome and Related Disorders, Vol. 7, no. 4, pp. 279-287, 2009.
104. K. Garber, "Aspirin for cancer chemoprevention: still a headache?" Journal of the National Cancer Institute, Vol. 96, no. 4, pp. 252-253, 2004.
105. R. B. Ness and C. Cottreau, "Possible role of ovarian epithelial inflammation in ovarian cancer," Journal of the National Cancer Institute, Vol. 91, no. 17, pp. 1459-1467, 1999.
106. D. K. Biswas, Q. Shi, S. Baily et al., "NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis," Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, no. 27, pp. 10137-10142, 2004.
107. L. A. deGraffenried, B. Chandrasekar, W. E. Friedrichs et al., "NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen," Annals of Oncology, Vol. 15, no. 6, pp. 885-890, 2004.
108. A. E. Wallace, D. A. Gibson, P. T. K. Saunders, and H. N. Jabbour, "Inflammatory events in endometrial adenocarcinoma," Journal of Endocrinology, Vol. 206, no. 2, pp. 141-157, 2010.
109. A. B. Alvero, "Recent insights into the role of NF-κB in ovarian carcinogenesis," Genome Medicine, Vol. 2, no. 8, article 56, 2010.
110. C. de Luca and J. M. Olefsky, "Inflammation and insulin resistance," FEBS Letters, Vol. 582, no. 1, pp. 97-105, 2008.
111. M. Y. Donath and S. E. Shoelson, "Type 2 diabetes as an inflammatory disease," Nature Reviews Immunology, Vol. 11, no. 2, pp. 98-107, 2011.
112. K. H. Seo, H.-S. Lee, B. Jung et al., "Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-κB activation," Cancer Research, Vol. 64, no. 18, pp. 6482-6488, 2004.
113. F. Modugno, R. B. Ness, C. Chen, and N. S. Weiss, "Inflammation and endometrial cancer: a hypothesis," Cancer Epidemiology Biomarkers and Prevention, Vol. 14, no. 12, pp. 2840-2847, 2005.
114. C. la Vecchia, S. H. Giordano, G. N. Hortobagyi, and B. Chabner, "Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle," Oncologist, Vol. 16, no. 6, pp. 726-729, 2011.
115. K. B. Michels, C. G. Solomon, F. B. Hu et al., "Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study," Diabetes Care, Vol. 26, no. 6, pp. 1752-1758, 2003.
116. L. L. Lipscombe, P. J. Goodwin, B. Zinman, J. R. McLaughlin, and J. E. Hux, "The impact of diabetes on survival following breast cancer," Breast Cancer Research and Treatment, Vol. 109, no. 2, pp. 389-395, 2008.
117. C. J. Currie, C. D. Poole, S. Jenkins-Jones, E. A. M. Gale, J. A. Johnson, and C. L. Morgan, "Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival," Diabetes Care, Vol. 35, no. 2, pp. 299-304, 2012.
118. J.-Y. Chen, W.-K. Chiou, W.-Y. Chou, and J.-D. Lin, "The impact of type 2 diabetes mellitus on mortality in hospitalized female cancer patients in Taiwan," Asia-Pacific Journal of Clinical Oncology, 2013.
119. S. Liao, J. Li, W. Wei et al., "Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature," Asian Pacific Journal of Cancer Prevention, Vol. 12, no. 4, pp. 1061-1065, 2011.
120. L. Sciacca, A. Costantino, G. Pandini et al., "Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism," Oncogene, Vol. 18, no. 15, pp. 2471-2479, 1999.
121. R. Novosyadlyy, D. E. Lann, A. Vijayakumar et al., "Insulinmediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes," Cancer Research, Vol. 70, no. 2, pp. 741-751, 2010.
122. H. Nyholm, H. Djursing, C. Hagen, T. Agner, P. Bennett, and B. Svenstrup, "Androgens and estrogens in post-menopausal insulin-treated diabetic women," The Journal of Clinical Endocrinology and Metabolism, Vol. 69, no. 5, pp. 946-949, 1989.
123. L. Vona-Davis and D. P. Rose, "Type 2 diabetes and obesity metabolic interactions: common factors for breast cancer risk and novel approaches to prevention and therapy," Current Diabetes Reviews, Vol. 8, no. 2, pp. 116-130, 2012.
124. B. S. Katzenellenbogen and M. J. Norman, "Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulinlike growth factor-I, serum, and estrogen," Endocrinology, Vol. 126, no. 2, pp. 891-898, 1990.
125. M. L. Panno, M. Salerno, V. Pezzi et al., "Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells," Journal of Cancer Research and Clinical Oncology, Vol. 122, no. 12, pp. 745-749, 1996.
126. L. Mauro, M. Salerno, M. L. Panno et al., "Estradiol increases IRS-1 gene expression and insulin signaling in breast cancer cells," Biochemical and Biophysical Research Communications, Vol. 288, no. 3, pp. 685-689, 2001.
127. A. Purohit, S. P. Newman, and M. J. Reed, "The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer," Breast Cancer Research, Vol. 4, no. 2, pp. 65-69, 2002.
128. A. Di Cristofano and L. H. Ellenson, "Endometrial carcinoma," Annual Review of Pathology, Vol. 2, pp. 57-85, 2007.
129. S. S. Jick, A. M. Walker, and H. Jick, "Estrogens, progesterone, and endometrial cancer," Epidemiology, Vol. 4, no. 1, pp. 20-24, 1993.
130. K. E. Anderson, E. Anderson, P. J. Mink et al., "Diabetes and endometrial cancer in the Iowa Women's Health Study," Cancer Epidemiology Biomarkers and Prevention, Vol. 10, no. 6, pp. 611-616, 2001.
131. Y. Zhang, Z. Liu, X. Yu et al., "The association between metabolic abnormality and endometrial cancer: a large casecontrol study in China," Gynecologic Oncology, Vol. 117, no. 1, pp. 41-46, 2010.
132. E. Friberg, C. S. Mantzoros, and A. Wolk, "Diabetes and risk of endometrial cancer: a population-based prospective cohort study," Cancer Epidemiology Biomarkers and Prevention, Vol. 16, no. 2, pp. 276-280, 2007.
133. H. Vainio, R. Kaaks, and F. Bianchini, "Weight control and physical activity in cancer prevention: international evaluation of the evidence," European Journal of Cancer Prevention, Vol. 11, supplement 2, pp. S94-S100, 2002.
134. L. J. Schouten, R. A. Goldbohm, and P. A. van den Brandt, "Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study," Journal of the National Cancer Institute, Vol. 96, no. 21, pp. 1635-1638, 2004.
135. S. C. Modesitt and J. R. Van Nagell Jr., "The impact of obesity on the incidence and treatment of gynecologic cancers: a review," Obstetrical and Gynecological Survey, Vol. 60, no. 10, pp. 683-692, 2005.
136. I. Bruchim, R. Sarfstein, and H. Werner, "The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches," Frontiers in Endocrinology, Vol. 5, p. 76, 2014.
137. T. Wang, T. E. Rohan, M. J. Gunter et al., "A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers," Cancer Epidemiology Biomarkers and Prevention, Vol. 20, no. 5, pp. 971-977, 2011.
138. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2012," CA: A Cancer Journal for Clinicians, Vol. 62, no. 1, pp. 10-29, 2012.
139. B. T. Hennessy, R. L. Coleman, and M. Markman, "Ovarian cancer," The Lancet, Vol. 374, no. 9698, pp. 1371-1382, 2009.
140. V. Beral, R. Doll, C. Hermon et al., "Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls," The Lancet, Vol. 371, no. 9609, pp. 303-314, 2008.
141. L. Poretsky and M. F. Kalin, "The gonadotropic function of insulin.," Endocrine Reviews, Vol. 8, no. 2, pp. 132-141, 1987.
142. R. J. Chang, R. M. Nakamura, H. L. Judd, and S. A. Kaplan, "Insulin resistance in nonobese patients with polycystic ovarian disease," Journal of Clinical Endocrinology and Metabolism, Vol. 57, no. 2, pp. 356-359, 1983.
143. A. I. Adler, N. S. Weiss, M. L. Kamb, and J. L. Lyon, "Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States)," Cancer Causes and Control, Vol. 7, no. 4, pp. 475-478, 1996.
144. J.-Y. Lee, I. Jeon, J. W. Kim, Y.-S. Song, J.-M. Yoon, and S. M. Park, "Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies," International Journal of Gynecological Cancer, Vol. 23, no. 3, pp. 402-412, 2013.
145. L. Wideroff, G. Gridley, L. Mellemkjaer et al., "Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark," Journal of the National Cancer Institute, Vol. 89, no. 18, pp. 1360-1365, 1997.
146. S.-F. Lo, S.-N. Chang, C.-H. Muo et al., "Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients," International Journal of Cancer, Vol. 132, no. 1, pp. 182-188, 2013.
147. H. A. Risch, "Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone," Journal of the National Cancer Institute, Vol. 90, no. 23, pp. 1774-1786, 1998.
148. M.-R. Shen, A.-C. Lin, Y.-M. Hsu et al., "Insulin-like growth factor 1 stimulates KCl cotransport, which is necessary for invasion and proliferation of cervical cancer and ovarian cancer cells," The Journal of Biological Chemistry, Vol. 279, no. 38, pp. 40017-40025, 2004.
149. Y. Tanaka, H. Kobayashi, M. Suzuki, Y. Hirashima, N. Kanayama, and T. Terao, "Genetic downregulation of pregnancy-associated plasma protein-A (PAPP-A) by bikunin reduces IGF-I-dependent Akt and ERK1/2 activation and subsequently reduces ovarian cancer cell growth, invasion and metastasis," International Journal of Cancer, Vol. 109, no. 3, pp. 336-347, 2004.
150. E. J. Lee, C. Mircean, I. Shmulevich et al., "Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion," Molecular Cancer, Vol. 4, article 7, 2005.
151. T. V. Clendenen, E. Lundin, A. Zeleniuch-Jacquotte et al., "Circulating inflammation markers and risk of epithelial ovarian cancer," Cancer Epidemiology Biomarkers and Prevention, Vol. 20, no. 5, pp. 799-810, 2011.
152. A. Evangelou, S. K. Jindal, T. J. Brown, and M. Letarte, "Down-regulation of transforming growth factor β receptors by androgen in ovarian cancer cells," Cancer Research, Vol. 60, no. 4, pp. 929-935, 2000.
153. E. Giovannucci, D. M. Harlan, M. C. Archer et al., "Diabetes and cancer: a consensus report," CA: A Cancer Journal for Clinicians, Vol. 60, no. 4, pp. 207-221, 2010.
154. L. G. Hemkens, R. Bender, U. Grouven, and P. T. Sawicki, "Insulin glargine and cancer," The Lancet, Vol. 374, no. 9703, pp. 1743-1744, 2009.
155. S. Jabbour, "Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both?" International Journal of Clinical Practice, Vol. 62, no. 6, pp. 845-847, 2008.
156. C. J. Currie, C. D. Poole, and E. A. M. Gale, "The influence of glucose-lowering therapies on cancer risk in type 2 diabetes," Diabetologia, Vol. 52, no. 9, pp. 1766-1777, 2009.
157. J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir, and G. Steineck, "Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden," Diabetologia, Vol. 52, no. 9, pp. 1745-1754, 2009.
158. H. M. Colhoun, "Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group," Diabetologia, Vol. 52, no. 9, pp. 1755-1765, 2009.
159. L. G. Hemkens, U. Grouven, R. Bender et al., "Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study," Diabetologia, Vol. 52, no. 9, pp. 1732-1744, 2009.
160. S. J. Pocock and L. Smeeth, "Insulin glargine and malignancy: an unwarranted alarm," The Lancet, Vol. 374, no. 9689, pp. 511-513, 2009.
161. M. Janghorbani, M. Dehghani, and M. Salehi-Marzijarani, "Systematic review and meta-analysis of insulin therapy and risk of cancer," Hormones and Cancer, Vol. 3, no. 4, pp. 137-146, 2012.
162. R. Ljung, M. Talbäck, B. Haglund, J. M. Jonasson, S. Gudbjörnsdòttir, and G. Steineck, "Insulin glargine use and short-term incidence of breast cancer a four-year population-based observation," Acta Oncologica, Vol. 51, no. 3, pp. 400-402, 2012.
163. S. Suissa, L. Azoulay, S. Dell'Aniello, M. Evans, J. Vora, and M. Pollak, "Long-term effects of insulin glargine on the risk of breast cancer," Diabetologia, Vol. 54, no. 9, pp. 2254-2262, 2011.
164. M. K. Leow, "Basal insulin and cardiovascular and other outcomes," The New England Journal of Medicine, Vol. 367, no. 18, pp. 1763-1764, 2012.
165. D. M. Nathan, J. B. Buse, and M. B. Davidson, "Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American diabetes association and the European association for the study of diabetes," Diabetes Care, Vol. 32, no. 1, pp. 193-203, 2009.
166. R. Giannarelli, M. Aragona, A. Coppelli, and S. Del Prato, "Reducing insulin resistance with metformin: the evidence today," Diabetes & Metabolism, Vol. 29, no. 4, part 2, pp. 6-S28, 2003.
167. R. J. Shaw, K. A. Lamia, D. Vasquez et al., "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin," Science, Vol. 310, no. 5754, pp. 1642-1646, 2005.
168. A. DeCensi, M. Puntoni, P. Goodwin et al., "Metformin and cancer risk in diabetic patients: a systematic review and metaanalysis," Cancer Prevention Research, Vol. 3, no. 11, pp. 1451-1461, 2010.
169. G. W. D. Landman, N. Kleefstra, K. J. J. van Hateren, K. H. Groenier, R. O. B. Gans, and H. J. G. Bilo, "Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16," Diabetes Care, Vol. 33, no. 2, pp. 322-326, 2010.
170. Z. B. Mei, Z. J. Zhang, C. Y. Liu et al., "Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis," PLoS ONE, Vol. 9, no. 3, Article ID e91818, 2014.
171. H. Noto, A. Goto, T. Tsujimoto, and M. Noda, "Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis," PLoS ONE, Vol. 7, no. 3, Article ID e33411, 2012.
172. M. Martin and R. Marais, "Metformin: a diabetes drug for cancer, ora cancer drug for diabetics?" Journal of Clinical Oncology, Vol. 30, no. 21, pp. 2698-2700, 2012.
173. R. Rattan, R. Ali Fehmi, and A. Munkarah, "Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis," Journal of Oncology, Vol. 2012, Article ID 928127, 12 pages, 2012.
174. E. J. Gallagher and D. Leroith, "Diabetes, cancer, and metformin: connections of metabolism and cell proliferation," Annals of the New York Academy of Sciences, Vol. 1243, no. 1, pp. 54-68, 2011.
175. H. Lee, H. J. Park, C.-S. Park et al., "Response of breast cancer cells and cancer stem cells to metformin and hyperthermia alone or combined," PLoS ONE, Vol. 9, no. 2, Article ID e87979, 2014.
176. D. G. Hardie, "Neither LKB1 nor AMPK are the direct targets of metformin," Gastroenterology, Vol. 131, no. 3, pp. 973-975, 2006.
177. R. J. O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, "Metformin inhibits mammalian target of rapamycin - dependent translation initiation in breast cancer cells," Cancer Research, Vol. 67, no. 22, pp. 10804-10812, 2007.
178. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, "Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells," Cancer Research, Vol. 66, no. 21, pp. 10269-10273, 2006.
179. I. N. Alimova, B. Liu, Z. Fan et al., "Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro," Cell Cycle, Vol. 8, no. 6, pp. 909-915, 2009.
180. B. Liu, Z. Fan, S. M. Edgerton et al., "Metformin induces unique biological and molecular responses in triple negative breast cancer cells," Cell Cycle, Vol. 8, no. 13, pp. 2031-2040, 2009.
181. M. Zakikhani, R. J. O. Dowling, N. Sonenberg, and M. N. Pollak, "The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase," Cancer Prevention Research, Vol. 1, no. 5, pp. 369-375, 2008.
182. V. N. Anisimov, L. M. Berstein, P. A. Egormin et al., "Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice," Experimental Gerontology, Vol. 40, no. 8-9, pp. 685-693, 2005.
183. M. B. Schneider, H. Matsuzaki, J. Haorah et al., "Prevention of pancreatic cancer induction in hamsters by metformin," Gastroenterology, Vol. 120, no. 5, pp. 1263-1270, 2001.
184. C. Algire, M. Zakikhani, M.-J. Blouin, J. H. Shuai, and M. Pollak, "Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth," Endocrine-Related Cancer, Vol. 15, no. 3, pp. 833-839, 2008.
185. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, "Metformin and reduced risk of cancer in diabetic patients," British Medical Journal, Vol. 330, no. 7503, pp. 1304-1305, 2005.
186. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., "Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer," Journal of Clinical Oncology, Vol. 27, no. 20, pp. 3297-3302, 2009.
187. Z.-J. Zhang and S. Li, "The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis," Diabetes, Obesity and Metabolism, Vol. 16, no. 8, pp. 707-710, 2014.
188. R. J. Stevens, R. Ali, C. R. Bankhead et al., "Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials," Diabetologia, Vol. 55, no. 10, pp. 2593-2603, 2012.
189. N. F. Col, L. Ochs, V. Springmann, A. K. Aragaki, and R. T. Chlebowski, "Metformin and breast cancer risk: a metaanalysis and critical literature review," Breast Cancer Research and Treatment, Vol. 135, no. 3, pp. 639-646, 2012.
190. H. Hauner, "The mode of action of thiazolidinediones," Diabetes/Metabolism Research and Reviews, Vol. 18, supplement 2, pp. S10-S15, 2002.
191. D. Panigrahy, S. Huang, M. W. Kieran, and A. Kaipainen, "PPARγ as a therapeutic target for tumor angiogenesis and metastasis," Cancer Biology and Therapy, Vol. 4, no. 7, pp. 687-693, 2005.
192. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, "Safety issues and prospects for future generations of PPAR modulators," Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, Vol. 1771, no. 8, pp. 1065-1081, 2007
193. K. Ohta, T. Endo, K. Haraguchi, J. M. Hershman, and T. Onaya, "Ligands for peroxisome proliferator-activated receptory inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells," The Journal of Clinical Endocrinology & Metabolism, Vol. 86, no. 5, pp. 2170-2177, 2001.
194. C. Blanquicett, J. Roman, and C. M. Hart, "Thiazolidinediones as anti-cancer agents," Cancer Therapy, Vol. 6, pp. 25-34, 2008.
195. J. Berger and D. E. Moller, "The mechanisms of action of PPARs," Annual Review of Medicine, Vol. 53, pp. 409-435, 2002.
196. D. Panigrahy, L. Q. Shen, M. W. Kieran, and A. Kaipainen, "Therapeutic potential of thiazolidinediones as anticancer agents," Expert Opinion on Investigational Drugs, Vol. 12, no. 12, pp. 1925-1937, 2003.
197. D. Panigrahy, S. Singer, L. Q. Shen et al., "PPARy ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis," The Journal of Clinical Investigation, Vol. 110, no. 7, pp. 923-932, 2002.
198. E. Saez, J. Rosenfeld, A. Livolsi et al., "PPAR" signaling exacerbates mammary gland tumor development, Genes & Development, Vol. 18, no. 5, pp. 528-540, 2004.
199. +/- double mutant mice," International Journal of Cancer, Vol. 116, no. 4, pp. 495-499, 2005.
200. E. Saez, P. Tontonoz, M. C. Nelson et al., "Activators of the nuclear receptor PPARy enhance colon polyp formation," Nature Medicine, Vol. 4, no. 9, pp. 1058-1061, 1998.
201. C. Koro, S. Barrett, and N. Qizilbash, "Cancer risks in thiazolidinedione users compared to other anti-diabetic agents," Pharmacoepidemiology and Drug Safety, Vol. 16, no. 5, pp. 485-492, 2007
202. R. Govindarajan, L. Ratnasinghe, D. L. Simmons et al., "Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes," Journal of Clinical Oncology, Vol. 25, no. 12, pp. 1476-1481, 2007
203. M. E. Ramos-Nino, C. D. MacLean, and B. Littenberg, "Association between cancer prevalence and use of thiazolidinediones: results from the vermont diabetes information system," BMC Medicine, Vol. 5, article 17, 2007
204. X. He, F. J. Esteva, J. Ensor, G. N. Hortobagyi, M.-H. Lee, and S.-C. J. Yeung, "Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer," Annals of Oncology, Vol. 23, no. 7, Article ID mdr534, pp. 1771-1780, 2012.
205. C.-H. Tseng, "Pioglitazone does not affect the risk of ovarian cancer: analysis of a nationwide reimbursement database in Taiwan," Gynecologic Oncology, Vol. 131, no. 1, pp. 135-139, 2013.
206. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, "Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials," Diabetes Care, Vol. 31, no. 7, pp. 1455-1460, 2008.
207. M. Monami, I. Dicembrini, and E. Mannucci, "Thiazolidine-diones and cancer: results of a meta-analysis of randomized clinical trials," Acta Diabetologica, Vol. 51, no. 1, pp. 91-101, 2014.